## 1 Data Descriptor Template

2

#### 3 Title

4 WearGait-PD: An Open-Access Wearables Dataset for Gait in Parkinson's Disease and Age-5 Matched Controls

6

## 7 Authors

Anthony J. Anderson<sup>1\*</sup>, David Eguren<sup>1\*</sup>, Michael A. Gonzalez<sup>1\*</sup>, Naima Khan<sup>1</sup>, Sophia
Watkinson<sup>1</sup>, Michael Caiola<sup>1</sup>, Siegfried S Hirczy<sup>2</sup>, Cyrus P. Zabetian<sup>2,3</sup>, Kelly Mills<sup>4</sup>, Emile
Moukheiber<sup>4</sup>, Laureano Moro-Velazquez<sup>5</sup>, Najim Dehak<sup>5</sup>, Chelsie Motely<sup>4</sup>, Brittney C. Muir<sup>2</sup>,
Ankur Butala<sup>4</sup>, and Kimberly Kontson<sup>1</sup>

- 12
- 13 \*These authors contributed equally to the manuscript.

# 1415 Affiliations

- 16 1. US Food and Drug Administration, Center for Devices and Radiological Health, Office of
- 17 Science and Engineering Laboratories, Silver Spring, MD, USA
- 18 2. VA Puget Sound Healthcare System, Seattle, WA, USA
- 19 3. Department of Neurology, University of Washington, Seattle, WA, USA
- 20 4. Johns Hopkins University School of Medicine, Baltimore, MD USA
- 21 5. Johns Hopkins University Whiting School of Engineering, Baltimore, MD, USA
- 22
- 23 corresponding author: Kimberly Kontson (Kimberly.Kontson@fda.hhs.gov)
- 24

## 25 Abstract

26 Wearable movement sensors are powerful tools for objectively characterizing and quantifying 27 movement. They enhance the precise characterization of gait, balance, and motor symptoms 28 in Parkinson's disease and related disorders, facilitating in-clinic and remote assessments, 29 disease management, and therapeutic intervention development. Access to high-quality data 30 from these sensors can accelerate discoveries in this clinical population. The WearGait-PD 31 open-access dataset contains raw inertial measurement unit (IMU) and sensorized insole data 32 from individuals with PD and age-matched controls, synchronized to a gait walkway reference 33 system. IMU data include 3-degree of freedom (DOF) acceleration, rotational velocity, 34 magnetic field strength, and orientation for each of 13 sensors on the participant's body. 35 Sensor insole data include absolute pressure from 16 sensors in each insole and 3-DOF 36 acceleration and rotational velocity. Walkway data include 2D position and relative pressure 37 for each active sensor during every footfall. Frame-by-frame annotation of participant actions 38 during gait and balance tasks was incorporated using synchronized video cameras. All data 39 were associated with demographic information and clinical evaluations (e.g., medications, 40 DBS-status, MDS-UPDRS scores).

41

## 42 Background & Summary

43 Parkinson's disease (PD) is a progressive neurodegenerative disorder that often 44 impairs gait and balance, resulting in reduced mobility and independence, and diminished 45 quality of life<sup>1-3</sup>. Wearable movement sensors have emerged as powerful tools for objectively 46 characterizing and quantifying movement. These offer the potential to enhance the precise 47 characterization of gait, balance, and motor symptoms in Parkinson's disease (PD) and related disorders, facilitating in-clinic and remote assessments, disease management, and therapeutic 48 intervention development<sup>4-7</sup>. In contrast, current clinical assessments of gait and balance are 49 semi-quantitative but remain largely qualitative, relying on subjective observations and 50 51 Not Bathenreneiponestand hervice and h 52 assessments as part of routine clinical practice<sup>11</sup>, remote patient monitoring<sup>12,13</sup>, and objective 53 endpoint measures for the regulatory evaluation of new drugs and medical devices<sup>14</sup>. By 54 providing continuous, high-resolution data on mobility-related health, these sensors and their 55 associated algorithms can identify motor signs of PD, track disease progression, and offer a 56 more complete picture of an individual's functional status<sup>15-17</sup>. This data-driven approach can 57 potentially transform PD treatment, ultimately improving patient outcomes and quality of life.

58

59 Despite the potential of wearable movement sensors to improve the treatment of PD, their 60 translation and widespread clinical adoption have been limited due to various scientific, technical, economic, and regulatory issues<sup>18-20</sup>. However, efforts are underway across 61 62 academia, the medical device industry, and regulatory bodies to overcome these limitations. 63 For instance, academic-led consortiums, such as Mobilise-D, are working to establish, verify, 64 and validate digital mobility outcomes, creating a framework for their use in clinical settings<sup>21</sup>. 65 Medical device developers have created wrist-worn devices that monitor the presence of 66 upper limb symptoms of PD and incorporate these measurements into clinician-facing dashboards in an aim to improve treatment decisions<sup>22,23</sup>. Additionally, the FDA has issued 67 guidance on using digital health technologies for remote data acquisition in clinical 68 69 investigations<sup>24</sup> and participates in the Digital Health Measurement Collaborative Community 70 (DATAcc) by the Digital Medicine Society, while the European Medicines Agency recently 71 approved a digitally-derived measure for use in Duchenne Muscular Dystrophy clinical trials<sup>14</sup>. 72 These activities indicate a growing recognition by regulatory organizations of the 73 transformative potential of the technology.

74

75 The need for high-quality, diverse, and well-annotated data remains a significant obstacle to 76 the development, validation, and clinical translation of wearable sensor digital health 77 technologies. As digital health technologies rely on a combination of computing platforms, 78 sensors, and algorithms<sup>24</sup>, data are a fundamental requirement at every stage of development, from prototyping through clinical trials<sup>25</sup>. However, obtaining high-quality movement data 79 80 from people with PD is challenging due to the high costs associated with data collection, the 81 fragility of the population, and the necessity for skilled clinicians to score and annotate the 82 data. These barriers create a development landscape where only well-funded organizations, 83 public or private, have the resources to participate in the innovation process, limiting the 84 diversity of ideas and approaches explored.

85

86 Open-access datasets offer one solution to the challenge posed by the lack of data in the 87 development of wearable technologies for PD. By providing high-value clinical datasets to the 88 research and development communities, open-access data efforts can democratize the 89 innovation process, enabling a wider range of researchers and developers to contribute to 90 advancing these technologies. Open-access datasets also promote reproducibility by allowing 91 researchers and developers to validate their findings independently and with diverse data. While several open-access wearable sensor and smartphone datasets for PD already exist<sup>26-33</sup>, 92 93 their overall utility may be limited by: (1) a primary focus on wrist-based monitoring, which 94 may not capture the full spectrum of gait and balance impairments, (2) a lack of associated 95 clinical information, such as disease severity scales and medication status, (3) insufficient 96 contextual information surrounding the data, such as time-series descriptions of specific 97 locomotor activities, and (4) a lack of reference measurements for the analytical validation of algorithms<sup>25</sup>. Addressing these limitations is crucial for streamlining the integration of 98 99 wearable sensors for clinical use in PD.

100

101 In response to these limitations, we present a large, multi-site, multi-modal open dataset 102 (WearGait-PD) of older adults with and without PD, engaged in both structured and semi-103 structured gait and balance tasks while wearing a full-body suite of sensors (Figure 1). This 104 dataset fills several vital gaps in the field, as it: (1) provides data from a full-body sensor suite 105 of inertial measurement units and sensorized insoles, (2) includes comprehensive clinical 106 information, such as Movement Disorder Society – Unified Parkinson's Disease Rating Scale 107 (MDS-UPDRS) scores and demographic details for each participant, (3) offers frame-by-frame, 108 human-readable annotations applied by two expert reviewers based on video assessment, 109 with clinician annotation of PD-specific symptoms such as freezing of gait, and (4) incorporates 110 ground truth measurements from a pressure-sensing walkway for independent validation of 111 digitally-derived metrics. By making this dataset publicly available to the research and medical 112 product development communities, we aim to accelerate innovation and ultimately access to 113 effective digital health technologies for assessing gait and balance in PD. 114



115Clinical DataDatabaseData Quality Control116Figure 1: Overview of data workflow for the WearGait-PD dataset. Sensor data were collected117via a set of wearable sensors (IMUs and sensorized insoles) and reference systems (cameras118and a sensorized walkway). The sensor data were processed, time synchronized, visualized,119and reviewed before uploaded to the public repository. Clinical data included demographic120information and results from clinical tests when possible.

121 122

#### 123 Methods

#### 124 Participants

125 At the time of submission, 126 participants were included in the dataset. Sixty-one PD 126 participants (25F/36M) with an average age of 66 ± 9 years and modified Hoehn & Yahr score of 2.15 ± 0.48 were included. The total MDS-UPDRS Part III score for these participants ranged 127 128 from 6-46, with a mean and standard deviation of  $24 \pm 10$ . The protocol did not require 129 participants to perform tasks in a specific medication state (i.e., ON or OFF). Instead, the time 130 elapsed since their last PD medication dose was recorded as a proxy. A total of 41 freezing of 131 gait events were captured across five unique PD participants. Within the PD group, 158 stagger 132 events were captured. Sixty-five control participants (40F/25M) with an average age of 76 ± 9

133 years were also included. Within this control group, 163 staggering events were captured.

134

#### 135 Inclusion/Exclusion Criteria

The study included adults (≥18 years) with physician-diagnosed PD and controls without PD. Exclusion criteria encompassed conditions that could prevent safe task performance, including non-neurological disorders significantly affecting speech, vision, or balance, cognitive or psychological impairments, or pregnancy. These criteria allowed for the inclusion of participants with a wide variety of typical and mildly pathological movement characteristics within the control group (e.g., individuals with essential tremor were not excluded, as we aimed to avoid spectrum bias by having only controls).

- 144 Consent and Ethics
- 145 Written informed consent was obtained from all study participants, including permission to 146 publish de-identified data openly. These data were collected under the Johns Hopkins School
- 147 of Medicine (JHM) IRB00234370 with an IRB Authorization Agreement (95-CDRH-2021-12-18)
- and VA IRB01702255 with an IRB Authorization Agreement (2023-CDRH-095), for which FDAis the relying institution.
- 150
- 151 <u>Sensor Systems</u>

The following sensor systems were used during the collection of data for this study. All studysites used the same acquisition software versions to maintain consistency.

154

Movella/Xsens MTw Awinda Inertial Measurement Units (IMUs): MTw Awinda is a wireless
 human motion tracking sensor suitable for real-time applications. Each sensor was 47 x 30 x
 13 mm. Each sensor communicated wirelessly with one of two base stations. Each base station
 was connected to a computer running the MT Manager 2019.1.1 acquisition software.

159

Moticon OpenGo Sensor Insoles: Moticon OpenGo is a wireless in-shoe system with Bluetooth<sup>™</sup>- and Wi-Fi-enabled electronics. Each sensor insole is designed to be used inside a shoe and measures plantar pressure distribution at the sole of foot with sixteen distributed pressure sensors. An on-board sensor at the center of the insole measures acceleration and rotation of the foot along three axes. The insoles slip into the shoes of the participant and a mobile Android application (OpenGo Mobile App Version 03.11.00) was used to control data acquisition.

167

ProtoKinetics Pressure Walkway: The 16-foot x 2-foot ProtoKinetics Zeno<sup>™</sup> Walkway Gait
 Analysis System detects pressure data and uses that data to define foot contacts. The walkway
 was equipped with over 18,000 individual sensors that each registered 16 different activation
 levels. Each sensor was 0.5" x 0.5" (1.27 cm x 1.27 cm). The ProtoKinetics Movement Analysis
 Software (PKMAS) 6.00c3 was used for data acquisition and raw data export.

173

GoPro HERO10 Black Video Camera: Two GoPro cameras were used in this study to film the
 participants from the frontal and sagittal planes as they completed each task. Each camera
 recorded video at 50 fps with a resolution of 1080p using either the linear or wide camera
 lens. The video compression was set to H.264 + HEVC. The cameras were triggered wirelessly
 via remote control by experimenters during gait and balance tasks.

- 179
- 180 Experimental Protocol
- 181

182 Study Sites

183 Data were collected across four study sites: FDA Office of Science and Engineering Labs (FDA), 184 Johns Hopkins Outpatient Center (JHOC), Johns Hopkins Bayview Campus (Bayview), and the 185 VA Puget Sound Health Care System Center for Limb Loss and Mobility (VA-Seattle). Subject 186 identifiers specific to each study site were used to denote the location at which data were 187 collected. The prefix 'FHC' is associated with the FDA site, 'NLS' is associated with the JHOC 188 site, prefix 'HC' is associated with the Bayview site, and prefixes 'WPD' and 'WHC' are 189 associated with the VA-Seattle site. Staff at each study site were trained on the same 190 equipment and the same experimental protocol was used across all sites.

191

#### 192 Participant Preparation

193 IMU sensors were attached to the participant's body at the following locations (see Figure 2):

- 194 Mid forehead
- 195 Xiphoid process of sternum

- L4/L5 of lower back
  - Right/left wrist halfway between the ulnar and radial styloid processes
  - Right/left lateral thigh, midway between greater trochanter of femur and head of fibula
  - Right/left lateral shank, midway between head of fibula and center of lateral malleolus
  - Right/left ankle, just above the lateral malleolus
  - Right/left dorsum of feet 50% of distance between 1st and 5th metatarsal bases and 50% of distance between distal end of 3rd metatarsal and center of anterior aspect of talus.
- 204 205
- 206



207 Left View Front View Right View 2 2 2 2
208 Figure 2: (Left) Locations and orientations of IMU sensors on the body and (Right) the
209 reference frames for both the IMUs and insoles.

The sensor locations and orientations were standardized and consistently applied across all
participants and study sites. Each participant was fitted with Moticon OpenGo sensor insoles
placed directly in the shoes.

214

215 Tasks

216 Once prepped with all study equipment, participants were video-recorded and asked to 217 perform specific tasks. Most tasks required the participants to make several passes along the 218 16-foot pressure walkway, where a pass constituted walking one length of the walkway. A list 219 of the tasks performed is below, with the abbreviations used in data file names in parentheses. 220 Throughout these task descriptions, the term 'mat' is synonymous with 'walkway'. 221

- SelfPace (SP): Participants started approximately 5 feet off the mat, walked at a self-selected pace across the mat and approximately 5 feet off the other side of the mat.
   Participants turned around off the mat and repeated this pass until a total of 4 passes were made.
- HurriedPace (HP): Participants started approximately 5 feet off the mat, walked at a hurried pace across the mat and approximately 5 feet off the other side of the mat.
   Participants turned around off the mat and repeated this pass until a total of 4 passes were made.
- SelfPace\_mat (SPm): Participants repeated the SelfPace walking task as above but remained on the mat the entire time. Participants started on the mat, walked at a self-selected pace across the mat, stopped, and turned around at the other end of the mat. Participants repeated this until a total of 4 passes were made.

200 201 202

203

196

197

198

234 HurriedPace mat (HPm): Participants repeated the HurriedPace walking task as above but remained on the mat the entire time. Participants started on the mat, 235 236 walked at a hurried pace across the mat, stopped, and turned around at the other end of the mat. Participants repeated this until a total of 4 passes were made. 237 238 SelfPace matTURN (SPmT): Participants repeated the SelfPace mat walking task as • 239 above but were instructed to alternate between left and right turns. Participants 240 started on the mat, walked at a self-selected pace across the mat, stopped, and turned around at the other end of the mat. Participants repeated this until a total of 241 242 5 passes were made so that two turns in each direction were captured. 243 TandemGait (TG): Participants made 2 full passes on the mat while doing a tandem • 244 gait walk (walking heel to toe). Participants remained on the mat the entire time and 245 turned around naturally after the first pass. 246 Timed Up and Go (TUG): Participants started seated in a chair with armrests with • 247 their back against the chair. The participant rose from the chair, walked to the other 248 end of the mat at a comfortable, self-selected pace, and turned at a line taped on 249 the mat 3m (9ft 10in) from the chair front. From there, they walked back to the 250 chair, and sat down. Participants were instructed to only use the armrests as 251 needed. Participants did NOT need to cross their arms when standing and sitting. 252 The *front* legs of the chair were placed on the starting line on the mat and turns 253 were made on the mat. The participant completed 3 trials of the TUG test within one continuous recording. 254 255 Balance (B): Participants started this task off the mat, typically near the midpoint of • 256 the mat on the side. For each of 6 subtasks, the participant was asked to step onto 257 the mat, complete the balance subtask for 10 seconds, and then step off the mat. 258 • Standing with eyes open and feet shoulder width apart 259 o Standing with eyes closed and feet shoulder width apart 260 Standing with eyes open and feet together 0 261 Standing with eyes closed and feet together 0 262 Standing with eyes open and right foot heel touching the left foot toe 0 263 Standing with eyes open and left foot heel touching the right foot toe 0 264 265 SelfPace\_doorpat (SPdoorpat): A mock door frame approximately 3 ft x 8 ft was • 266 placed across the center of the mat over a pattern of lines perpendicular to the 267 direction of travel. Participants started approximately 5 feet off the mat, walked at a 268 self-selected pace across the mat through the mock door frame and approximately 5 269 feet off the other side of the mat. Participants turned around off the mat and 270 repeated this pass until a total of 4 passes were made. 271 272 FreeWalk (FW): Participants started approximately 5 feet off the mat, walked at a • 273 self-selected pace across the mat and out of the session room into the hallway. 274 Participants proceeded to walk through a defined path within the research facility as 275 they navigated hallways, a small staircase (if available), and sitting down/rising from 276 a chair before returning to the session room. Each study site had a unique free walk 277 path, which is described in greater detail in the Synapse repository. 278

- 279 Tasks were completed sequentially in the order listed above.
- 280
- 281 <u>Clinical Information and Assessments</u>

282 In coordination with the clinical collaborator at each study site, information about medication 283 usage and clinical evaluations was obtained from the most recent patient visit when available. 284 If medical records were not available, medication usage and any other relevant medical history 285 were obtained by participant self-report. The MDS-UPDRS was used as the main 286 clinician/patient reported outcome measure. When possible, the MDS-UPDRS evaluation was 287 completed by a trained specialist the day of the session to ensure the evaluation corresponded 288 with the data collected. For instances where the MDS-UPDRS was not captured the day of data 289 collection, the most recent MDS-UPDRS evaluation was used with the date captured denoted 290 in the clinical spreadsheet.

- 291 Additional clinical information collected included:
- 292 Time since first diagnosis
- Current medication type and dose
- Time since last medication dose
- Current physical/occupational therapy status and frequency of visits
- DBS (if patient has it); Bilateral vs unilateral; location of electrodes; date of surgery
- Basic demographics (age, gender, sex, height, weight, race)
- Modified Hoehn and Yahr scale score
- 299

#### 300 Data Processing

301

302 Movella/Xsens MTw Awinda Inertial Measurement Units (IMUs): During data collection, each 303 MTw IMU internally sampled data at 1000 Hz, applied factory calibration, and low pass filtered 304 at 184 Hz. An onboard stap-down integration algorithm processed these samples, computing 305 orientation and velocity increments that were transmitted wirelessly at 100 Hz. The MT 306 Manager software was used for post-processing, applying the manufacturer's XKF3-hm 307 Kalman filter to generate 100 Hz outputs of acceleration, angular velocity, orientation, and 308 gravity-compensated (free) acceleration. For a detailed description of the system's signal 309 processing architecture, refer to the MTw Awinda whitepaper<sup>34</sup>.

310

311 ProtoKinetics Pressure Walkway: After data collection, the ProtoKinetics software 312 automatically labels groups of active sensor cells as belonging to either the left or right foot. 313 Additional manual preprocessing of the walkway data was completed to ensure left and right 314 footfalls were correctly identified. Partial footfalls on the walkway were labeled as 'Other' 315 rather than left or right. After the footfall labeling was completed, a research staff member 316 conducted a review of the labeling to ensure no mistakes or mislabeled footfalls exist.

317

318 Moticon OpenGo Sensor Insoles: Sensor insole waveforms were reviewed visually. Although 319 infrequent, instances of desynchronization occurred during wireless communication between 320 the sensor insoles and the Moticon acquisition App. This resulted in asynchronous data 321 capture or prolonged recording from one insole even after the 'Stop' command was issued. 322 When such desynchronization was detected, the data from the insoles were adjusted—shifted 323 and/or trimmed—within the OpenGo Software to ensure proper alignment between both 324 insoles and to accurately synchronize the cessation of recording with the conclusion of the 325 data stream.

327 GoPro HERO10 Black Video Camera: Manual annotation of the participant's activity using the 328 video data was also completed. After the data collection session ended, the videos recorded 329 for each trial from the side and front views were combined and deidentified. The result was a single video with both views shown side-by-side, where each view had the participant's face 330 331 cropped out. On some occasions, only a single video camera view was available. The primary 332 annotation process of the session videos used the Video Labeler application in MATLAB to 333 provide a frame-by-frame annotation of general and clinical events for the duration of each 334 task video, with clinical events being labeled concurrently with general events.

After the primary annotations were completed, a research staff member conducted a review of the existing annotations to ensure no mistakes or mislabeled events existed. If any clinical events were identified by the research staff during primary annotation or review, those events were reviewed by at least one neurologist collaborator at Johns Hopkins or the VA to confirm or reject the annotation of the clinical event.

340 Detailed definitions of the general and clinical gait events used in this dataset can be found in 341 the Data Description – Video Annotation section of the Wiki.. These definitions were provided

to ensure consistency across annotators.

#### 343 Data Synchronization and Alignment

344 Each task included four main data sources: IMUs, sensor insoles, walkway, and video cameras. 345 The walkway served as the primary clock for all system synchronization and alignment. Upon 346 starting a recording in the PKMAS walkway software, a 3.3 V TTL square wave signal was sent 347 from the ProtoKinetics walkway interface box to the Sync In port of each MTw Awinda base 348 station. The MT Manager software for the MTw Awinda IMUs was configured to start 349 recording upon receipt of the TTL signal from the walkway. Synchronization between the 350 sensor insoles and walkway was achieved by setting the Moticon OpenGo App to produce an 351 audible beep during recording start/stop. The audio signal from the phone was converted to 352 a 3.3 V square wave via custom electronics from Moticon, which was read into the 353 ProtoKinetics walkway interface box and subsequently the walkway acquisition software. 354 Walkway, sensor insole, and IMU systems were all set to record data at 100 Hz.

Two video cameras set up perpendicular and parallel to the direction of participant travel collected data to facilitate frame-by-frame annotation of participant movement. A green light connected to the ProtoKinetics walkway interface box was programmed to turned on for five seconds when recording was initiated. The video cameras started recording prior to the walkway to ensure each video camera captured the green light turning on. The green light was then used to align the two video streams to each other as well as the walkway. For each task, the general order of operations for collecting synchronized data were as follows:

- 362
- 1. Prime IMU acquisition software on computers to accept a sync signal.
- 363
- 364
  3. Start the trial in walkway acquisition software (which simultaneously starts recording IMU data and triggers green light).

2. Start the video cameras using a remote control.

- 365 366
- 4. Start recording sensor insole data in phone app.

367 After a participant completed a task, the opposite order of operations was taken to stop 368 recording data:

- 369 1. Stop recording sensor insole data in phone app.
- Stop recording the trial walkway acquisition software (which simultaneously stops the IMU recording).

- 3. Stop the video cameras using the remote control.
- 373 Figure 3 shows a schematic of the overall hardware synchronization approach.



374

Figure 3: Synchronization approach across the walkway, IMU, sensor insole, and camerasystems.

MATLAB scripts were written to read in the raw data from each sensor modality, align the data
in time, and export to the MAT and CSV file formats. A brief description of the subroutines
implemented to generate these aligned MAT and CSV files follows.

Align walkway and IMU data  $\rightarrow$  Since the IMU system received a hardwired sync signal from the walkway system (primary clock) at the beginning of recording, the data from the IMU sensors and walkway were concatenated without further alignment. Occasionally, the IMU sensor data contained more or fewer time points than the walkway data. When shorter, padding of NaN was added to the end of the IMU data. When longer, the data that extended past the end of the length of the walkway data were discarded. Benchtop characterization confirmed the walkway and IMU data were aligned within 2 frames at 100 Hz.

394 During pilot work, visual inspection of the aligned walkway and sensor insole data revealed a 395 consistent time delay in the sensor insole signals relative to the walkway signals. We attributed 396 this delay to the non-deterministic nature of the Android operating system running the 397 Moticon Open Go App, which led to lag between stopping the sensor insole recording and the 398 sync signal being sent to the walkway acquisition software. Benchtop experiments were 399 conducted to characterize this delay across all study sites, sensor insole sizes, and data 400 collection sessions. Results indicated site-specific, consistent delays that were independent of 401 insole size and data collection session. These site-specific corrections were applied to the 402 sensor insole data during initial import and alignment processing to address the constant bias 403 component of the delay. However, cross-correlation analyses indicated that the delay

between walkway and insole waveforms has both a constant component and small random
 components. Dataset users should proceed with caution when interpreting data that depends
 on precise alignment of the sensor insoles with the walkway and IMU systems. For relevant
 analyses, users may consider first aligning the insole total force waveforms to the walkway
 foot pressure waveforms using cross-correlation or other methods. More details on the
 system characterization can be found in the Data Description – Sensor insole sync
 characterization section of the Wiki.

411

412 Align walkway and video annotation data  $\rightarrow$  The annotation file exported from MATLAB's 413 Video Labeler App was formatted such that the string variable for each annotation event at a 414 given time point was listed under a 'GeneralEvent' or 'ClinicalEvent' column. The annotation 415 data were resampled from 50 Hz to 100 Hz. Alignment between the walkway and video 416 annotation data was achieved using the green light connected to the walkway system. A 417 MATLAB script automatically detected the first video frame in which the green light turned on 418 and used this to align the video annotation data with the start of the walkway data. All video 419 data before the green light turned on were discarded.

The output of these processes is a set of aligned time-series data across each data collectionsource (Figure 4A), as well as the spatial information collected by the walkway (Figure 4B).



422

Figure 4: (A) Time series data from a participant with Parkinson's disease, during which a freezing of gait (FoG) episode occurred. The data include annotation of activities captured via camera, 3-DOF accelerometer and gyroscope data from an IMU, and force data from a pair of sensorized insoles. The portion of the data with a gray background corresponds to the spatial information in part b. (B) Spatial data from a participant with Parkinson's disease, during one pass across a sensorized walkway. Blue regions indicate areas of walkway activation, with darker colors corresponding to higher forces.

429 act 430

## 431 Data Records

432 Detailed descriptions of the experimental set-up, data collection approach, processing, and 433 data quality control for the WearGait-PD dataset are provided in the <u>main Wiki page</u> on the 434 Synapse platform (SAGE Bionetworks) The <u>Data Access</u> tab within the Wiki provides further 435 instructions on how to gain access to the data. 437 There are two main parts to the data: the clinical/demographic information and the sensor 438 data. All clinical and demographic information is available for all PD patients and control 439 participants and can be found in CSV spreadsheets. In these spreadsheets, each row 440 constitutes one participant, with the first column listing the participant ID. All participant IDs 441 are alphanumeric, with the letters denoting the study site at which the participant was 442 recorded. All columns are labelled with the variable name. The clinical and demographic 443 information contained within these spreadsheets was briefly described in the Methods -444 Clinical Information and Assessments section of this paper. When available, the response to 445 each question of the MDS-UPDRS was included, allowing for maximum flexibility in use of the 446 scores.

447

Formatting scripts were written to align all wearables and reference sensor data and save data as MAT files and comma-separated value (CSV) files. For a given participant, there are 8 CSV files (1 file/task) that contain the annotation events, walkway data, insole data, and IMU data. The CSV files follow the naming convention of <SubjectID>\_<Task Name>.csv (see Methods – Tasks section of this paper for task descriptions). These data can be found in a folder labelled (CSV files' in the Synapse repository. Of note, the use of the word 'mat' in the task names refers to participants performing a task entirely on the walkway mat.

455

456 The same data for each participant is also represented as one MATLAB MAT file that contains

457 8 structure variables for each task, with each task containing 8 fields (Figure 5).

458

Current Folder Name A NLS036.mat NLS036.mat (MAT-file)		$\overline{\mathbf{v}}$				
		0		HurriedPace ×		
		~		1x1 struct wit	th 8 fields	
H Name	Value			Field ~	Value	
E Balance	1x1 struct			C Annotation	4229x2 timetable	
HurriedPace	1x1 struct			Walkway	4229x8 timetable	
E HurriedPace_mat	1x1 struct			MU acc	4229x84 timetable	
E SelfPace	1x1 struct			MU_gyr	4229x45 timetable	
E SelfPace_mat	1x1 struct			IMU_mag	4229x39 timetable	
E SelfPace_matTURN	1x1 struct			IMU_vellnc	4229x39 timetable	
🗄 TUG	1x1 struct			IMU_orient	4229x91 timetable	
E TandemGait	1x1 struct					

459 460

461

463

•

Annotation:

461 A brief description of the fields within each task structure variable is below:

464 • Walkway: tx8 timetable containing sensor and contact walkway data 465 • Insole: tx38 timetable containing insole data 466 IMU acc: tx84 timetable containing Acc and FreeAcc variables for each IMU • 467 and insole 468 • IMU\_gyr: tx45 timetable containing gyroscope data for each IMU and insole 469 IMU\_mag: tx39 timetable containing magnetometer data for each IMU • 470 IMU\_velInc: tx39 timetable containing  $\Delta v$  data for each IMU • 471 • IMU orient: tx91 timetable containing  $\Delta q$  and roll, pitch, yaw data for each IMU 472

Figure 5: Sample MAT file structure for one participant.

For missing numeric data due to connectivity issues, sensor malfunctions, or lack of instrumentation for a given participant/task, NaN values were used. The data alignment process also used NaN values at the beginning and/or end to pad the time series, so NaN values in these locations are expected. Sensors not available during a given data collection were excluded from CSV output files but represented as NaN columns in the MAT files. For the

tx2 timetable containing video annotation information

GeneralEvent and ClinicalEvent variables containing frame-by-frame annotations, the string "unlabeled" was used to represent portions of a trial that did not match any annotation category (e.g., shuffling at the end of a trial instead of standing). In total, there were 346 variables associated with each task. A description of all the variables as well as reference coordinate systems for the IMUs, walkway, and sensor insoles is provided in the <u>Data</u> <u>Description</u> section of the Wiki.

## 485 **Technical Validation**

486 Data quality is of the utmost importance in the curation of an open-access dataset. A quality 487 assurance process was implemented to ensure consistent and accurate data collection. 488 Specifically, a core experimental protocol was developed and reviewed by each researcher, 489 including cross-site review of how the protocol was executed by various researchers. This 490 protocol detailed the steps involved in system set-up, participant preparation, data collection, 491 and data processing and export. All files were renamed to include the participant ID and task 492 abbreviation immediately after data collection to minimize the risk of file loss due to incorrect 493 folder allocation. For those modalities that required more manual processing (i.e., walkway 494 data and video annotation data), a second researcher reviewed the primary processing 495 completed by the first researcher to ensure proper footfall identification and conformance 496 with the agreed upon annotation event definitions. An Excel spreadsheet accessible to all 497 researchers was also used to track the progression of data processing, from initial collection 498 to MAT and CSV file generation.

499

484

After MAT and CSV files were created, a data quality control process on those files was implemented through a series of automatic and manual data checks that involved visual inspection of data streams by a researcher to identify data cleanliness and validity issues.

503

505

508

509

510

511

512

513

514

515 516

504 Specifically, this process identified issues related to:

- Processing and inclusion of all tasks in the MAT and CSV files
- Integrity of individual IMU sensor data, including the identification of sensor values
   outside of expected ranges
  - Unexpected missing columns of data
  - Unexpected large gaps in data
  - Expectations around the variable type for a given data variable (e.g., annotations contain no numeric data, IMU data does not contain any errant non-numeric data)
  - Video annotation events and expectations surrounding the inclusion of specific events for specific tasks
    - Alignment of all data, with a particular focus on walkway pressure and sensor insole force data

517 If an issue was identified, a second researcher was assigned to review and address the issue. 518 Once an issue was addressed, the relevant files were put through the data quality control 519 process again to confirm that all issues were resolved before the final MAT file and final set of 520 CSVs files were generated and included in the dataset.



522

Figure 6: Quality control results for each trial, applied prior to inclusion of data to the WearGait-PD dataset. A trial is defined by a single task performed by a single participant. Category values add up to greater than 968 as the 'False Flag', 'Correctable Issues', and 'Partial Data Loss' categories were not mutually exclusive.

527

Of the 968 total trials that comprised the initial release of data, the majority of files passed all 528 529 quality checks (651 trials) and another portion were flagged as potential issues but required 530 no corrective action (58 trials) (Figure 6). Of the remaining trials with confirmed issues, 99 531 trials contained fixable issues such as the placement of files in the wrong location, missed 532 annotation frames, or insole desynchronization. Each of these passed subsequent quality 533 checks. The remaining 173 files had significant data loss (data dropout of 7 frames or greater, 534 or loss of a sensor), either from connectivity or battery issues. While these data could not be 535 recovered, the remaining data present in these trials were checked to confirm they were clean 536 and valid. Overall, 82% of trials were considered complete, while the remaining 18% of trials 537 passed all quality control checks with the exception that they were missing some data from 538 either the insoles or IMUs.

539

## 540 Usage Notes

541 To access the data on Synapse, users must first register with Synapse.org. Users register by 542 providing a name and valid e-mail address and agreeing to the Synapse Terms and Conditions 543 of Use and reviewing the Privacy Policy and Code of Conduct. As part of the registration 544 process, users must agree to each of the terms of the Synapse Pledge, recapitulating the 545 themes of the Synapse Terms and Conditions of Use, Privacy Policy, and Code of Conduct. 546 Specifically, this pledge requires users to confirm they will (1) adhere to the community 547 standards of inclusion and respect, (2) adhere to all conditions and data use limitations, (3) act 548 ethically and responsibly, (4) use appropriate physical, technical, and administrative measures 549 to keep data secure and protect participant's privacy, (5) support open access best practices, 550 (6) credit research participants and all data sources, (7) confirm the data will not be used for 551 marketing and/or advertising, and (8) report suspected data breaches and/or misuse to the 552 Synapse team.

553

554

## 555 Code Availability

Using MATLAB 2023a, we developed code to implement the quality control process detailed
in the Technical Validation section. This code is available in the 'Code' folder under 'Files' on
the Synapse repository.

## 560 Acknowledgements

561 The authors would like to thank all study participants for their enthusiastic participation. We'd 562 also like to thank the FDA research fellows (Ms. Isabella Zuccaroli, Mr. Bryan Sabogal, Mr. Brian Nogh) who have assisted in data collection and processing, as well as former FDA staff members (Dr. Edward Nyman) who contributed to the development of the experimental protocol. The authors would also like to thank research coordinators from Johns Hopkins Bayview Medical Center (Ms. Jackie Langdon, Ms. Meredith Dobrosielski, and Ms. Crystal Szczesny) for their assistance with subject recruitment and consent, and Dr. Peter Abadir for his thoughtful insight into the experimental protocol. In this work, researchers at the Johns Hopkins University were partially funded by the Consolidated Anti-Aging Foundation.

570

## 571 Author contributions

Conceptualization (KK, MC, AB), Methodology (All authors), Software (MC, MG, AA, KK),
Validation (AA, MG, KK, MC), Formal Analysis (KK, AA, MG, DE), Investigation (KK, AA, DE, MG,
NK, SW, MC, CM, BM, SZ, KM, AB, EM), Resources (KK, BM, AB), Data Curation (KK, AA, DE,
MG, MC, NK, SW, SZ, AB, KM, EM), Writing – Original Draft (AA, DE, MG, KK), Writing – Review
and Editing (All authors), Visualization (KK, AA, MG), Supervision (KK, BM, AB), Project
Administration (KK, BM, AB, CM), Funding Acquisition (KK, BM, AA, LM, AB)

### 579 Competing interests

580 The authors declare no competing interests.

581

586

578

#### 582 Disclaimer:

583 The mention of commercial products, their sources, or their use in connection with material 584 reported herein is not to be construed as either an actual or implied endorsement of such 585 products by the Department of Health and Human Services.

#### 587 References

- 5881DeMaagd, G. & Philip, A. Parkinson's disease and its management: part 1: disease589entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharmacy590and therapeutics 40, 504 (2015).
- 5912Duncan, R. P. & Earhart, G. M. Measuring participation in individuals with Parkinson592disease: relationships with disease severity, quality of life, and mobility. *Disability*593and rehabilitation **33**, 1440-1446 (2011).
- 5943Santos García, D. *et al.* Non-motor symptoms burden, mood, and gait problems are595the most significant factors contributing to a poor quality of life in non-demented596Parkinson's disease patients: Results from the COPPADIS Study Cohort. *Parkinsonism*597*Relat Disord* 66, 151-157 (2019). <a href="https://doi.org:10.1016/j.parkreldis.2019.07.031">https://doi.org:10.1016/j.parkreldis.2019.07.031</a>
- Schlachetzki, J. C. *et al.* Wearable sensors objectively measure gait parameters in
  Parkinson's disease. *PloS one* **12**, e0183989 (2017).
- 6005Morris, R. et al. Validity of Mobility Lab (version 2) for gait assessment in young601adults, older adults and Parkinson's disease. Physiol Meas 40, 095003 (2019).602https://doi.org:10.1088/1361-6579/ab4023
- 6036Salis, F. et al. A multi-sensor wearable system for the assessment of diseased gait in604real-world conditions. Front Bioeng Biotechnol 11, 1143248 (2023).605https://doi.org:10.3389/fbioe.2023.1143248
- 606 7 Sotirakis, C. *et al.* Identification of motor progression in Parkinson's disease using 607 wearable sensors and machine learning. *npj Parkinson's Disease* **9**, 142 (2023).
- 6088Goetz, C. G. *et al.* Movement Disorder Society-sponsored revision of the Unified609Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric610testing results. *Mov Disord* 23, 2129-2170 (2008).

611 https://doi.org:10.1002/mds.22340

Evers, L. J. W., Krijthe, J. H., Meinders, M. J., Bloem, B. R. & Heskes, T. M. Measuring
Parkinson's disease over time: The real-world within-subject reliability of the MDSUPDRS. *Mov Disord* 34, 1480-1487 (2019). <u>https://doi.org:10.1002/mds.27790</u>

615	10	Regnault, A. et al. Does the MDS-UPDRS provide the precision to assess progression
616		in early Parkinson's disease? Learnings from the Parkinson's progression marker
617		initiative cohort. J Neurol 266, 1927-1936 (2019). https://doi.org:10.1007/s00415-
618		<u>019-09348-3</u>
619	11	Guerra, A., D'Onofrio, V., Ferreri, F., Bologna, M. & Antonini, A. Objective
620		measurement versus clinician-based assessment for Parkinson's disease. Expert Rev
621		Neurother 23, 689-702 (2023). https://doi.org:10.1080/14737175.2023.2229954
622	12	Shah, V. V. et al. Digital biomarkers of mobility in Parkinson's disease during daily
623		living. Journal of Parkinson's disease 10, 1099-1111 (2020).
624	13	Shah, V. V. et al. Gait and turning characteristics from daily life increase ability to
625		predict future falls in people with Parkinson's disease. Frontiers in neurology 14,
626		1096401 (2023).
627	14	Servais, L. et al. Stride Velocity 95th Centile: Insights into Gaining Regulatory
628		Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne
629		Muscular Dystrophy Trials. J Neuromuscul Dis <b>9</b> , 335-346 (2022).
630		https://doi.org:10.3233/JND-210743
631	15	Klucken, J., Krüger, R., Schmidt, P. & Bloem, B. R. Management of Parkinson's disease
632		20 years from now: towards digital health pathways. Journal of Parkinson's disease 8,
633		S85-S94 (2018).
634	16	Mughal, H., Javed, A. R., Rizwan, M., Almadhor, A. S. & Kryvinska, N. Parkinson's
635		disease management via wearable sensors: a systematic review. IEEE Access 10,
636		35219-35237 (2022).
637	17	Rovini, E., Maremmani, C. & Cavallo, F. How wearable sensors can support
638		Parkinson's disease diagnosis and treatment: a systematic review. Frontiers in
639		neuroscience <b>11</b> , 288959 (2017).
640	18	Del Din, S., Kirk, C., Yarnall, A. J., Rochester, L. & Hausdorff, J. M. Body-worn sensors
641		for remote monitoring of Parkinson's disease motor symptoms: vision, state of the
642		art, and challenges ahead. Journal of Parkinson's disease 11, S35-S47 (2021).
643	19	Fasano, A. & Mancini, M. Wearable-based mobility monitoring: the long road ahead.
644		Lancet Neurol 19, 378-379 (2020). <u>https://doi.org:10.1016/S1474-4422(20)30033-8</u>
645	20	Espay, A. J. et al. A roadmap for implementation of patient-centered digital outcome
646		measures in Parkinson's disease obtained using mobile health technologies. Mov
647		Disord 34, 657-663 (2019). https://doi.org:10.1002/mds.27671
648	21	Rochester, L. et al. A Roadmap to Inform Development, Validation and Approval of
649		Digital Mobility Outcomes: The Mobilise-D Approach. Digit Biomark 4, 13-27 (2020).
650		https://doi.org:10.1159/000512513
651	22	US Food and Drug Administration - Center for Devices and Radiological Health.
652		NeuroRPM K221772 Approval Letter,
653		< <u>https://www.accessdata.fda.gov/cdrh_docs/pdf22/K221772.pdf</u> > (2023).
654	23	US Food and Drug Administration - Center for Devices and Radiological Health. Rune
655		Labs Kinematics System K213519 Approval Letter,
656		< <u>https://www.accessdata.fda.gov/cdrh_docs/pdf21/K213519.pdf</u> > (2022).
657	24	US Food and Drug Administration. Digital Health Technologies for Remote Data
658		Acquisition in Clinical Investigations - Guidance for Industry, Investigators, and Other
659		Stakeholders, < <u>https://www.fda.gov/media/155022/download</u> > (2023).
660	25	Goldsack, J. C. et al. Verification, analytical validation, and clinical validation (V3): the
661		foundation of determining fit-for-purpose for Biometric Monitoring Technologies
662		(BioMeTs). NPJ Digit Med 3, 55 (2020). <u>https://doi.org:10.1038/s41746-020-0260-4</u>
663	26	Bot, B. M. et al. The mPower study, Parkinson disease mobile data collected using
664		ResearchKit. Scientific data <b>3</b> , 1-9 (2016).

665	27	de Oliveira, C. E. N. et al. A public data set with ground reaction forces of human
666		balance in individuals with Parkinson's disease. <i>Frontiers in neuroscience</i> <b>16</b> , 865882
667		(2022).
668	28	Gilmore, G., Gouelle, A., Adamson, M. B., Pieterman, M. & Jog, M. Forward and
669		backward walking in Parkinson disease: a factor analysis. Gait & posture 74, 14-19
670		(2019).
671	29	Ribeiro De Souza, C. et al. A public data set of videos, inertial measurement unit, and
672		clinical scales of freezing of gait in individuals with parkinson's disease during a
673		turning-in-place task. Frontiers in Neuroscience 16, 832463 (2022).
674	30	Vergara-Diaz, G. et al. Limb and trunk accelerometer data collected with wearable
675		sensors from subjects with Parkinson's disease. Scientific Data 8, 47 (2021).
676	31	Zhang, W. et al. Multimodal data for the detection of freezing of gait in Parkinson's
677		disease. <i>Scientific data</i> <b>9</b> , 606 (2022).
678	32	Varghese, J. et al. Machine Learning in the Parkinson's disease smartwatch (PADS)
679		dataset. NPJ Parkinsons Dis 10, 9 (2024). https://doi.org:10.1038/s41531-023-00625-
680		7
681	33	Morgan, C. et al. A multimodal dataset of real world mobility activities in Parkinson's
682		disease. Sci Data 10, 918 (2023). https://doi.org:10.1038/s41597-023-02663-5
683	34	Paulich, M., Schepers, M., Rudigkeit, N. & Bellusci, G. Xsens MTw Awinda: Miniature
684		Wireless Inertial-Magnetic Motion Tracker for Highly Accurate 3D Kinematic
685		Applications. Xsens Technologies White Paper